Matthew Tappin, who serves as President, Software Products at Stem Inc (NYSE:STEM), disposed of 402 shares of the companys common stock on March 11, 2026. The shares were sold at $10.83 apiece, resulting in a total transaction value of $4,353.
At the time the sale was reported, the market price for Stem stock stood at $10.60. That level represents a roughly 12% decline over the prior week and a 30% decrease year-to-date, based on the trading figures noted alongside the transaction.
After completing the sale, Tappin retains direct ownership of 2,823 shares in the company. The disposition was carried out under the terms of a Rule 10b5-1 trading plan that Tappin adopted on March 18, 2025.
Separately, some equity research commentary referenced in relation to the company indicates differing views on Stems valuation and outlook. An InvestingPro analysis included with the transaction reporting characterizes the stock as appearing undervalued at current levels.
On the company performance front, Stem reported fourth-quarter and full-year 2025 results that included positive EBITDA, a point highlighted in recent corporate disclosures. That profitability measure was noted as part of the companys reported performance and transformation trajectory.
Despite the reported positive EBITDA, UBS has revised its view on the stocks forward price potential. The brokerage firm lowered its price target from $18 to $12 and retained a Neutral rating on the shares. UBS attributed the reduction in target price primarily to a slower software sales outlook and also cut its adjusted EBITDA estimates for 2026 through 2028.
Taken together, the insider sale, the companys recent profit metric, and the analyst revisions present a mixed set of signals for investors assessing Stem. The transaction was executed under a preexisting trading plan and does not introduce new corporate disclosures beyond the previously reported earnings and analyst updates.
Summary
Matthew Tappin sold 402 shares of Stem Inc. on March 11, 2026, under a Rule 10b5-1 plan, for $4,353. Stem reported positive EBITDA for Q4 and full-year 2025. UBS lowered its price target from $18 to $12 and trimmed adjusted EBITDA estimates for 2026-2028, citing slower software sales. InvestingPro analysis indicated the stock appears undervalued at current market levels.